Future BMS CEO Boerner Pleas For Patience As New Products Build Momentum
Earnings Report Was Preempted By C-Suite Change-Up
Executive Summary
Christopher Boerner, who will become CEO on 1 November, reported Q1 progress for new drugs Sotyktu, Camzyos and Opdualag, noting that greater growth for these early launches is still to come.
You may also be interested in...
Bristol’s New Launches Hit Reality As New Product Portfolio Forecast Is Revised
With slower than expected sales of some newer products, Bristol lowered mid-term guidance for its new product portfolio and extended the timeline for reaching the goal to 2026.
Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves
KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.
Amgen Falters In Core Immunology Business, But Help Is On The Horizon
Sales of Amgen’s key immunology drugs Otezla and Enbrel plunged in Q1, impacted by inventory and competition, but the company will add a new blockbuster when its Horizon acquisition closes in June.